Wissenschaft mit Auszeichnung: Herausragende Nachwuchsforscher auf der Jahrestagung der Deutschen…
Wund(er)heilung mit Amnion – DGFG erhält deutschen Wundpreis 2021
Ausschreibung DGNI-Pflege- und Therapiepreis 2022
Ausschreibung: Otsuka Team Award Psychiatry+ 2021
BGW-Gesundheitspreis 2022: Gute Praxis aus der Altenpflege gesucht!
5. Nürnberger Wundkongress vom 01. bis 02. Dezember 2022: „Wer…
2. Nationaler ITP Patiententag von Novartis am 10. September: Informationen…
20.-22.01.2022 online: ANIM: NeuroIntensivmediziner diskutieren neue Erkenntnisse zu COVID-19
8.-10. September 2021: Weimar Sepsis Update 2021 – Beyond the…
13.09. – 18.09.2021: Viszeralmedizin 2021
Unique features and innovative design
Roche Diabetes Care’s new Accu-Chek® Guide wireless blood glucose monitoring system offers smart solutions for easier testing
- Accuracy surpasses the ISO 15197:2013/EN ISO 15197:201510 requirements for blood glucose monitoring systems
- Easy-to-use with an intuitive user interface and improved testing experience
- Connectivity to the Accu-Chek Connect diabetes management system enables online data exchange with healthcare professionals and caregivers
Munich, Germany (September 12, 2016) – On August 31, 2016, Roche Diabetes Care received clearance by the U.S. Food and Drug Administration (FDA) for the new Accu-Chek Guide blood glucose monitoring system that has been designed to address previously unmet needs of patients and their healthcare professionals. The Accu-Chek Guide system offers a combination of unique features and an innovative design which make it easy and safe to use.
Designed to address unmet needs of people with diabetes
Appropriate use of SMBG (self-monitoring of blood glucose) can enhance diabetes self-management, and an increase in SMBG frequency is associated with a significant reduction in HbA1c values in patients on insulin therapy,1 as well as improved glycemic control with a reduced incidence of acute2,3 and longterm4-6 complications. Non-adherence to routine SMBG remains a common issue7 and people with diabetes report they would test more frequently if the procedure was easier and more discreet 8,9. The new Accu-Chek Guide system has been tailored to the specific needs of people with diabetes to make it a user-friendly system. In fact, 9 out of 10 (97%) participants surveyed agreed that the Accu-Chek Guide system is extremely easy to use14. Healthcare professionals can anticipate taking less time to train their patients on this new system, allowing them more time for valuable consult discussions.
SmartPack vial and easy-edge technology help make testing easier
Successful diabetes management relies on accurate and reliable information shared between people with diabetes, caregivers and healthcare professionals. Accu-Chek Guide offers Bluetooth® low energy connectivity to the Accu-Chek Connect diabetes management system, providing automatic data logging and secure online data sharing. Results can be transmitted wirelessly from the Accu-Chek Guide meter to the Accu-Chek Connect app on the user’s mobile device, and from there to the Accu-Chek Connect Online portal, so diabetes information can be viewed virtually anywhere for timely advice, as needed. This cloud-based solution provides a clear picture of what’s working for people with diabetes and what’s not. This approach can help turn reliable data into actionable information that can support improved outcomes for people with diabetes, their caregivers and healthcare professionals. Ultimately, connected systems can encourage patient adherence and bring relief to patients when they can make more sense of the data and make better decisions.
- Miller KM, et al. Diabetes Care 2013; 36: 2009-14
- Sämann A, et al. Diabetologia 2005; 48: 1965-70
- Weber C, et al. Curr Med Res Opin 2009; 25: 1197-207.
- ADA. Diabetes Care 2016, Standards of Medical Care in Diabetes; January 2016 Volume 39, Supplement 1 :s23-s81
- Diabetes Control and Complications Trial Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
- Nathan DM, et al. N Engl J Med 2005; 353: 2643-53
- Hansen MV, et.al. Diabetes Res Clin Pract. 2009;85(2):183–8
- Bergenstal R, et al. Diabetes Educ 2000; 26: 981-9.
- Ong, W.M., et al. Patient Prefer Adherence, 2014. 8: p. 237-46
- International Organization for Standardization (ISO). ISO 15197:2013 http://www.iso.org/iso/catalogue_detail?csnumber=54976 .
- Brazg RL, et al. J Diabetes Sci Technol 2013;7:144-152
- Brazg RL, Klaff LJ, Sussmann, AM, Parkin: Accu-Chek Guide Blood Glucose Monitoring System Exceeds International Accuracy Standards, Journal of Diabetes Science and Technology 1–2, DOI: 10.1177/1932296816652902
- Hinnen D, et al. J Diabetes Sci Technol. 2015 Mar; 9(2): 293–301
- Harvey C., et al., “Monitoring System With a Spill-Resistant Vial, Easier Strip Handling, and Connectivity to a Mobile App: Improvement of Patient Convenience and Satisfaction. Journal of Diabetes Science and Technology 1-6, DOI: 10.1177/1932296816658058
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
- For more information, please visit www.roche.com
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome.
- For more information please visit www.accu-chek.com
Roche Diagnostics, 12.09.2016 (tB).